Inactive Instrument

Mirati Therapeutics Share Price

MRTX

US60468T1051

Latest news : Mirati Therapeutics

24/01/24	British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says	RE
24/01/24	Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P Biotechnology Select Industry Index	CI
24/01/24	Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P TMI Index	CI
24/01/24	Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P Global BMI Index	CI
23/01/24	Bristol-Myers Squibb Closes Acquisition of Mirati Therapeutics	MT
23/01/24	Bristol-Myers Squibb Closes Mirati Therapeutics Acquisition	MT
23/01/24	Bristol Myers: acquisition of Mirati Therapeutics finalized
23/01/24	Mirati Therapeutics, Inc. Announces Management Changes	CI
23/01/24	Mirati Therapeutics, Inc.(NasdaqGM:MRTX) dropped from NASDAQ Composite Index	CI
22/01/24	Bristol-Myers Squibb Company completed the acquisition of Mirati Therapeutics, Inc. from a group of shareholders.	CI
22/01/24	Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index	CI
10/01/24	Mirati Therapeutics' Krazati Lung Cancer Treatment Gets EU Conditional Marketing Authorization	MT
08/01/24	Bristol Myers expects to launch 16 new products through 2030 - CEO	RE

More news

Analysts' recommendations: Mirati Therapeutics

20/12/23	Citigroup Downgrades Mirati Therapeutics to Neutral From Buy, Raises Price Target to $59 From $48	MT
07/11/23	Stifel Downgrades Mirati Therapeutics to Hold From Buy, Cuts Price Target to $59 From $83	MT
10/10/23	Scotiabank Upgrades Mirati Therapeutics to Sector Perform From Sector Underperform, Raises Price Target to $58 From $24	MT
10/10/23	TD Cowen Downgrades Mirati Therapeutics to Market Perform From Outperform	MT
10/10/23	Piper Sandler Downgrades Mirati Therapeutics to Neutral From Overweight, Raises Price Target to $58 From $45	MT

More recommendations

Press Releases: Mirati Therapeutics

11/01/24	Mirati Therapeutics - European Commission Approves KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation	AQ
10/01/24	European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation	PR
10/11/23	Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure	PR
08/11/23	MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX	BU
06/11/23	MHRA authorises new treatment for rare lung cancer	AQ

More press releases

News in other languages: Mirati Therapeutics

23/01/24	Bristol Myers : acquisition de Mirati Therapeutics finalisée
26/12/23	Bristol-Myers Squibb koopt RayzeBio
22/12/23	Bristol Myers comprará a Karuna Therapeutics por 14.000 millones de dólares
22/12/23	Bristol Myers rachète pour $14 mds Karuna Therapeutics et son traitement contre la schizophrénie
13/12/23	Pharma und Gesundheit: weitere Konsolidierung

More news

Managers and Directors: Mirati Therapeutics

Manager	Title	Age	Since
Sandra Ramos-Alves PSD	President	-	22/01/2024
Kimberly McCutcheon Jablonski SEC	Corporate Secretary	-	22/01/2024
Sophia Park PRN	Corporate Officer/Principal	-	22/01/2024

Director	Title	Age	Since
Konstantina Katcheves BRD	Director/Board Member	-	22/01/2024
Sandra Ramos-Alves BRD	Director/Board Member	-	22/01/2024
Kimberly McCutcheon Jablonski BRD	Director/Board Member	-	22/01/2024

More insiders

Mirati Therapeutics, Inc. is a commercial-stage oncology company. The Company is developing novel therapeutics to address the genetic and immunological promoters of cancer. The Company's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.

Employees

587

Sector

More about the company

Date	Insider	Type	Main position	Quantity	% Market Cap.
23/01/24	Bruce Carter	Issuer sale	Director	45,793	0.0653%
23/01/24	James Christensen	Issuer sale	Chief Technology Officer	468,410	0.6677%
23/01/24	Aaron Davis	Issuer sale	Director	97,845	0.1395%

Mirati Therapeutics Share Price

Stocks